Highlights Oct 12 - Oct 18, 2026
new every Sunday
This week brought a sharper split between mechanism and outcome: mouse research separated psilocybin's synaptic effects from hallucinatory behavior, while early OCD trials showed promise but exposed persistent evidence gaps. A major acquisition and a new training curriculum also signaled preparations for wider clinical use.
-
01
5-HT2A-Rezeptoren in kortikalen Schicht-5-Pyramidenneuronen vermitteln die neuroplastischen, nicht aber die halluzinogenen Wirkungen von Psilocybin
Mouse experiments tie psilocybin's synaptic remodeling, but not head-twitch behavior, to layer-5 cortical 5-HT2A receptors.
-
02
Drei randomisierte Psilocybin-Studien bei Zwangsstörungen zeigen Fortschritte, lösen aber das Verblindungsproblem nicht
Three randomized OCD studies suggest rapid psilocybin benefits, but small samples and unblinding still limit efficacy claims.
-
03
Big Pharma herontdekt psychedelica als medicijn: overname van Atai Beckley toont groeiende marktverwachtingen
Lilly's reported $3.6 billion Atai Beckley acquisition puts a major drugmaker behind late-stage 5-MeO-DMT development.
-
04
Brain entropy during a first psilocybin trip predicts later gains in psychological insight and well-being, while lasting brain changes remain limited
A 28-person study links acute brain entropy on psilocybin with later insight and well-being, but finds limited lasting neural change.
-
05
Betelnusskonsum vor bis zu 25.000 Jahren: Zahnfunde auf Sulawesi liefern frühe Hinweise auf psychoaktiven Pflanzengebrauch
Evidence from ancient teeth points to habitual betelnut use on Sulawesi up to 25,000 years ago, though its purpose remains unclear.
-
06
Ein internationales Autorenteam veröffentlicht nach mehrjähriger Arbeit ein Modellcurriculum für psychedelisch unterstützte Psychotherapie
An international model curriculum offers a common foundation for training in psychedelic-assisted psychotherapy and clinical practice.
-
07
The Psychedelic Practitioner Issue 7: Preparedness and the Systems Needed to Deliver Psychedelic Therapies
A delivery-focused review maps the staffing, workflows, compliance, reimbursement, and equity challenges facing psychedelic care.